Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update. This quarter reflects the progress we are making in...